Methods: After getting approval from hospital Ethical committee 140 patients of CSR were included in the study. The demographic details were noted and patients were randomized by lottery methods in two groups (group A& B). Group-A was observed for spontaneous resolution, routine treatment started if no improvement noted after 6 weeks of observation alone. Group B was given oral rifampicin 600mg per day for four weeks with liver function tests being done before commencement of treatment and after 2 weeks. Oral rifampicin was stopped if patient developed deranged liver function tests. Patients were followed up at 4 weeks for macular dryness and decrease macular thickness on optical coherence tomography(OCT). All the readings were carried out and noted by single person in order to minimize bias.
Incidence of visual loss in young adult men due to central serous chorioretinopathy is approximately Z1/10,000 2 which is 1.74-fold higher than females. 3 With a recurrence rate of 19.41%. 4 Risk factors include exogenous steroid, type A personality, pregnancy, smoking, Cushing syndrome, H.Pylori infection and systemic lupus erythematosis. 5 Central serous chorioretinopathy is thought to be caused by an impaired automatic response due to elevating circulating cortisol and epinephrine level which in turn affect the auto regulation of the choroidal circulation.
Specific psychological and personality profiles have been associated with CSCR but the exact link between anxiety-sensitive personalities and steroid biology has not been elucidated.
All this considered, it is clear that complex links between CSCR and corticosteroids are yet to be described. In this context, we have investigated and identified the mineralocorticoid receptor as a potential player in CSCR pathogenesis. This review will focus on recent findings that have furthered the epidemiology, the clinical understanding and the management of CSCR and will detail the possible role of the mineralocorticoid pathway in CSCR pathogenesis and treatment.
As central serious chorioretinopathy mainly effects young working male population, this novel treatment strategy would be tremendously beneficial in terms of early return to their activities and less socio-economic loss. Confirmation of efficacy of rifampicin opens the doors for this newer treatment modality.
METHODS

This Randomized control trial was done at Layton
Rahmatulla Benevolent Trust (LRBT) Free Eye and Cancer Hospital, Lahore from January 2017 to June 2017. Ethical approval was taken from hospital Ethical committee and written consent was taken from all the participants. Sample size was calculated considering 80% power of test (1-beta). Sample was collected by non-probability consecutive sampling.
The patients with age ranging from 20 to 50 presenting within 3 weeks of symptoms onset were included as we were looking for role of rifampicin in acute CSR. All those patients with disease duration of more than 6 months, recurrent disease, having another ocular pathology and deranged liver function tests were excluded from study. Rifampin may be of potential benefit to patients with CSC. Acute cases appear to respond most favorably.
DISCUSSION
Sub-retinal fluid may decrease with treatment, while sub-RPE fluid often persists. These early findings suggest a novel method for the treatment of chronic CSC and warrants further study.
The findings of our study confirms the efficacy of rifampicin and opens the doors for this newer treatment modality which would speed and recovery with high response rate,
CONCLUSION
We concluded that there is a significant difference in efficacy in terms of drying of macula in acute central serous chorioretinopathy with Rifampicin versus observation alone.
